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tion therapy with half-dose r:PA and abciximab reduces the rate of reinfarction across a 
broad range of patients compared with r-PA alone. The long-term implications of these 
findings on 1-year mortality awaits definition. 
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828-2 The Abciximab ST-Recovery ON AMI (ASTRONAMI) 
GUSTO V Substudy: Enhanced Early Speed, Stability, 
and Quality of Reperfueion With AntI-Platelet 
Augmented Thrombolytic Therapy for ST-Elevation AMI 
Mitchell W. Krucoff, Cynthia L. Green, Anatoly Langer, Brian Giblet, Paul W. Armstrong, 
Kathleen M. Trollinger, Suzanne W. Crater, Michael A. Lincoff, Robert M, Califf, Eric J, 
TOpoI, The ASTRONAMI-GUSTO V Investigators, Duke University Medical Center~Duke 
Clinical Research Institute, Durham, North Caro/ina, Cleveland Clinic Foundation, 
C/eve/and, Ohio. 
Background: In the GUSTO V study combined Rx with abciximab and low dose rPA was 
compared to full dose rPA alone in pts with ST elevation MI. Modality with Combo Rx 
was non-inferior, Mechanistic differences were not reported. 
Methods: In the ASTRONAMI substudy the speed, stability and microvascular quality of 
reperfusion were quantified by blinded core lab analysis of ST recovery from Rozinn 152 
continuous digital 12-lead ECG recordings as: 1 ) time (minutes) from onset of Rx to a) 1st 
50% ST recovery from peak (1 st 50% ST} and b) >4 hrs with >50% ST recovery (STA- 
BLE ST); 2) recurrent ischemia (RE-ST, as % of pts with ST re-elevation >150uV over 
recovery levels; and 3) ST level vs. time trend curve area (ST AREA in uV-min), respec- 
tively. 
Results: A total of 4,992 pt hrs of monitoring totaling 299,520 ECGs were analyzed from 
207 pts (108 Combo Rx, 99 rPA Rx). Clinical descriptors, time from chest pain to Rx, time 
to ST monitoring, duration of monitoring and peak ST levels were comparable. ST recov- 
e~ results were: 
Descriptor rPA Rx Combo Rx P value* 
1 =t 50=/= ST (%) 46 (19.0, 92.6) 34.0 (0, 66) .042 
STABLE ST (min) f 00 (42, 162) 65 (0, 112) .002 
RE-ST (%) 40.2 30.1 . f 55 
ST AREA (uV-min) 4782 (259, 9820) 2576 (0, 7716) .047 
* continuous variables: two-sample t-test, Wilcoxon rank sum test; discrete variables: 
likelihood ratio chi-square, Fisher's exact text. 
Conclusion: Thus, combined Rx with abciximab and low dose rPA improves the speed, 
stability and microvascutar quality of reperfusion in ST-elevation MI compared to rPA 
alone. 
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828-3 Combination Tenecteplase and Abciximab Results in 
More Complete ST Resolution: Findings from the 
ASSENT 3 ECG Subatudy 
Yulina Fu, Galen Wagner, Shaun Goodman, Frans Van de Werf, Christopher B. Granger, 
Paul W. Armstrong, for the ASSENT 3 Investigators, University of A/berta, Edmonton, 
A/berta, Canada. 
The ASSENT 3 study documented that the two experimental arms i.e. combination 
tenectsplase plus enoxaparin or half-dose tenecteplase and abciximab reduced the fre- 
quency of ischemic complications of acute myocardial infarction. The mechanism(s) for 
this benefit is unclear but combination therapy with fibrinolytic and glycoprotein lib/Ilia 
inhibitors has previously achieved more effective early reperfusion in phase 2 anglo- 
graphic trials whereas angiographic evaluation with low molecuJar weight heparin has 
shown less reocclusion. 
Accordingly we analyzed sequential ECG's at baseline, 60 and 180 minutes after enroll- 
ment in all patients in the ASSENT 3 study, in order to evaluate the 3 treatment groups 
(tenecteplase and enoxaparin [TNK/ENOX]; half dose tenecteplase and abciximab [1/2 
TNK/ABCX]; tanecteplase and unfractionated heparin [TNK/UH]). Amongst the 75% of 
the 6,095 patients who had technically suitable ECG data free of confounding factors, ST 
resolution compared to baseline is shown in the table, 
These data, in a large comprehensively studied AMI population, suggest better early 
myocardial perfusion with combination TNK-abciximab than TNK with either ENOX OR 
UH alone. They also suggest the clinical benefit of enoxaparin in ASSENT 3 is modu- 
lated by a mechanism different han early repertusion occurring later in the ischemic pro- 
cess. 
TNK/ENOX 1/2 TNK/ABCX TNK/UH 
60 min ECG n=1,506 n=1,472 n=1,483 
>=70% resolution 28.9 33.4* 31.9 
30-70% resolution 33.9 32.5 31.4 
<30% resolution 37.3 34.1 36.7 
180 min ECG n=1,463 n=1,461 n=1,416 
>=70% resolution 50.0 59.1 ** 48.0 
30-70% resolution 32.5 29.6 31.5 
<30% resolution 17.5 t 1.3 20.5 
*p=0.02 **p<0.001 
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828-4 Differential Impact of Antlthrombotlc Treatments 
Combined With Tenecteplaae in the Elderly With Acute 
Myocardial Infarction: Results From ASSENT-3 
Christooher B. Granoer. John H. Alexander, Emmanuel Lesaffre, Lars Wallentin, Paul W. 
Armstrong, Frans Van de Werf, Duke C/in/ca/Research Institute, Durham, North 
Carolina, Leuven Coordinating Centre, Leuven, Belgium. 
Background: Among patients with acute myocardial infarction (MI), the elderly are at par- 
ticularly high risk for death and bleeding complications, including with more aggressive 
antithrombotic strategies. 
Methods: In order to provide insight into risk and benefit in the elderly, we examined 
patients from the ASSENT-3 Trial with ST elevation MI, who were treated with tenect- 
eplase (TNK) and randomized to unfractionated heparin (UFH), enoxapadn, or abcix- 
imab with low dose heparJn (and half-dose TNK), 
Results: Of the 6095 patients enrolled, 13% (767) were >75 years of age. Compared to 
younger patients, patients > 75 had higher rates of death (17.9 vs 4.3%), intracraniat 
hemorrhage (ICH, 1.6 vs 0.8%), and bleeding. Older patients had higher rates of the effi- 
cacy + safety composite (death, reMI, refractory ischemia, ICH, and major bleeding) with 
abciximab than with enoxaparin or UFH (table), and the treatment effect of abciximab vs 
UFH was significantly less in older than in younger patients (interaction p<0.05). 
Conclusions: Elderly patients with acute MI are at high risk of death and bleeding, 
Although TNK with either enoxaparin or abciximab appeared to be more effective than 
with standard UFH in younger patients, TNK with abciximab as dosed in this trial was sig- 
nificantly less effective and may be unsafe in the elderly. For elderly patients, develop- 
ment of treatments with greater safety and effectiveness remains a high priority. 
>75 years (11=767) 
UHF Enoxaparin Abciximab p 
Death, reMI, refractory ischemia, ICH, 28.0 25.5 36.9 0.01 
major bleed (%) 
30-day death (%) 15.9 18.6 22.3 0.11 
ReMI (%) 6.3 2.3 3.0 0.07 
Major bleeding (%) 4.1 7.2 13.3 0.001 
ICH (%) 0.74 1.52 2.58 0.26 
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828-5 Lack of Improvement in ST Segment Resolution After 
the Combination Treatment of Abcixlmab With 
Reteplase Compared to Reteplase Alone for Acute 
Myocardial Infarction: Results From the GUSTO V- 
RESTART Subatudy 
Femando A. Cure, Marco Roffi, Narcis Pasca, Katherine E. Wolski, Eric J. Topoi, Michael 
S. Lauer, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: The combination of abciximab during reperfusion therapies is believed to 
enhance tissue level and microvascular perfusion. Resolution of ST-segment elevation 
after administration of thrombolytic therapy in patients with acute myocardial infarction is 
a marker of myocardial reperfusion and has an important predictive value of mortality. 
This study compared the extent of 60-minute ST-segment elevation resolution of patients 
treated with full dose of reteplase versus half-dose reteplase in combination with abcix- 
imab given at the normal dose from the GUSTO V-AMI trial. 
Methods: From a total of 16.588 patients enrolled in the GUSTO V-AMI trial, 1764 were 
prospectively included in the RESTART substudy and were randomized to the combina- 
tion of full dose abciximab and half dose of reteplase or full dose of reteplase alone. A 
baseline and 60-minute ECG was analyzed by a core lab to categorize 4 groups: com- 
plete resolution (>70%), partial resolution (<70%-30%), no resolution (<30%) and wors- 
ening ST-segment. 
Results: There was no difference in the clinical baseline variables between the two treat- 
ment groups, The results are summarized in the table. 
Reteplase Reteplase + Abciximab p value 
(n=871) (n=893) 
Complete Resolution (%) 32 34 0.37 
Partial Resolution (%) 29 27 0.35 
No Resolution (%) 19 18 0.59 
Worsening ST-segment (%) 20 20 0.95 
30-day Mortality (%) 5.1 4.7 0.73 
Conclusion: Patients treated with reduced doses of reteplase when administered in 
combination with abciximab are associated with similar extent of ST-segment elevation 
resolution as those treated with full dose reteplase alone. 
3:15 p.m. 
828-6 Risk and Benefit of  Half-Dose Lytlc Plus Abciximab 
Versus Lytic Alone for ST-Elevation Myocardial 
Infarction: A Mate-Analysis 
Freak W. Verheuat. University Medical Center Nijmegen, Nijmegen, The Netherlands. 
Background Angiogrephic trials have shown improved 60 and 90 minutes coronary 
patency with half-dose lytic plus abciximab versus lytic alone in ST-elevation MI (STEMI). 
These strategies have recently been evaluated in 2 phase III msgatrials for efficacy and 
